Testing a New COVID-19 Drug for Mild to Moderate Cases
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This trial tests a new drug, ratutrelvir, for people with mild to moderate COVID-19. It aims to find a safe and effective dose to help you feel better faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have tested positive for COVID-19 in the last 5 days (120 hours).
- Your COVID-19 symptoms must have started within the last 5 days.
- You must have at least one symptom (like fever, cough, or body aches) in the last 24 hours.
- You cannot have needed hospital care or oxygen therapy for your COVID-19.
- You must not have any serious liver or kidney problems or a weakened immune system.
- You cannot have received a COVID-19 vaccine in the last 4 months or plan to during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether PF-07321332 (with ritonavir) helps children under 18 who have COVID-19 at home but are at high risk of severe illness. It looks at whether starting treatment early can reduce progression to worse disease.
This trial looks at how well an antiviral works in the body when started early in people with COVID-19 symptoms. You may be able to join if you’re an otherwise healthy adult with confirmed infection and symptoms for less than 4 days.
This early-phase trial tests a new drug (called B10-FC) to see if it's safe and how the body processes it. It is given once to healthy adults, and later to people with mild or moderate COVID-19 who are at higher risk of getting very sick.
This trial studies a longer course of remdesivir combined with nirmatrelvir/ritonavir (Paxlovid) for immunocompromised patients who have persistent COVID-19. The goal is to see if this combination helps clear the virus better.
This study tests an experimental oral antiviral, secutrelvir, for people with mild to moderate COVID-19 who are not sick enough to need hospital care. The medicine aims to reduce symptoms and help you recover faster.
This trial tests whether Codivir can help people hospitalized with moderate COVID-19 recover better than a placebo (inactive pill). It will compare outcomes while participants receive standard hospital care.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.